Laboratory and clinical evaluation of rifampicin.
D000328:Adult; D000362:Agar; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001431:Bacteriological Techniques; D001437:Bacteriuria / Q000188:drug therapy*; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D003470:Culture Media; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects*; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009343:Neisseria / Q000187:drug effects; D011511:Proteus / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D012475:Salmonella / Q000187:drug effects; D012760:Shigella / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D003470:Culture Media; D000362:Agar